Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

Results from this pharmacokinetic study (n=48) show that a reduced ixazomib starting dose of 3mg should be recommended for patients with moderate or severe hepatic impairment compared to 4mg for patients with normal hepatic function.